In a phase Ib study of PLX3397 which is efficacy for patients with advanced solid tumors, CSF-1R signaling is interrupted by PLX3397 and the M2-like TAMs is significantly reduced at tumor sites in patients [64]. The gene discussed is CSF1R; the disease is neoplasm.